Anemia, Iron-Deficiency

• 

  Subject Areas on Research

  • A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5. 
  • A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD. 
  • A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. 
  • A reduced transferrin saturation is independently associated with excess morbidity and mortality in older adults with heart failure and incident anemia. 
  • AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia. 
  • An assessment of medical resource utilization and hospitalization cost associated with a diagnosis of anemia in women with obstetrical bleeding in the United States. 
  • Anemia and coronary artery disease: pathophysiology, prognosis, and treatment. 
  • Association of blood donation with iron deficiency among adolescent and adult females in the United States: a nationally representative study. 
  • Cases from the Osler Medical Service at Johns Hopkins University. Diffuse colonic angiodysplasia with chronic iron deficiency anemia. 
  • Caught on Capsule: Iron-deficiency Anemia Due to Hookworm Infection. 
  • Commentary on: ferrokinetics in the syndrome of familial hypoferremic microcytic anemia with iron malabsorption. 
  • Cord Blood Ferritin and Fibroblast Growth Factor-23 Levels in Neonates. 
  • Detection of iron deficiency in children with Down syndrome. 
  • Disorders of iron metabolism. 
  • Donor Iron Deficiency Study (DIDS): protocol of a study to test whether iron deficiency in blood donors affects red blood cell recovery after transfusion. 
  • Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis. 
  • Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. 
  • Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency. 
  • Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. 
  • Efficacy of iron-supplement bars to reduce anemia in urban Indian women: a cluster-randomized controlled trial. 
  • FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. 
  • Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. 
  • GI Evaluation of Iron Deficiency Anemia: Clinical Decision Support Tool. 
  • Hair Mercury Level is Associated with Anemia and Micronutrient Status in Children Living Near Artisanal and Small-Scale Gold Mining in the Peruvian Amazon. 
  • Health, nutrition and prosperity: a microeconomic perspective. 
  • Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. 
  • Host iron status and iron supplementation mediate susceptibility to erythrocytic stage Plasmodium falciparum. 
  • Household food insecurity is a risk factor for iron-deficiency anaemia in a multi-ethnic, low-income sample of infants and toddlers. 
  • How do I develop a process to effectively treat parturients with iron deficiency anemia? 
  • Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis. 
  • Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management. 
  • Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. 
  • Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron. 
  • Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. 
  • Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome. 
  • Iron Deficiency Anemia in Pregnancy. 
  • Iron deficiency and hair loss: the jury is still out. 
  • Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups. 
  • Iron deficiency in young Lebanese children: association with elevated blood lead levels. 
  • Iron deficiency: lessons from anemic mice. 
  • Iron metabolism: iron deficiency and iron overload. 
  • Management of Perioperative Iron Deficiency in Cardiac Surgery: A Modified RAND Delphi Study. 
  • Markers of Iron Flux during Testosterone-Mediated Erythropoiesis in Older Men with Unexplained or Iron-Deficiency Anemia. 
  • Maternal Perceived Stress during Pregnancy Increases Risk for Low Neonatal Iron at Delivery and Depletion of Storage Iron at One Year. 
  • Modulation of sulfur assimilation metabolic toxicity overcomes anemia and hemochromatosis in mice. 
  • Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). 
  • Nutrition and hearing loss: a neglected cause and global health burden. 
  • Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction: Design and Rationale for Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure. 
  • Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference. 
  • Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry. 
  • Prevalence of iron deficiency in children with Down syndrome. 
  • Proinflammatory state, hepcidin, and anemia in older persons. 
  • Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. 
  • Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design. 
  • Randomized trial of intravenous iron-induced hypophosphatemia. 
  • Response to Zhang et al. 
  • Review: In HF with iron deficiency, iron supplementation reduces HF admissions and improves cardiac function. 
  • Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose. 
  • Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. 
  • Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON-IDA/NEPHRO trials. 
  • Spotlight: Gastrointestinal Evaluation of Iron Deficiency Anemia. 
  • The association between serum copper and anaemia in the adult Second National Health and Nutrition Examination Survey (NHANES II) population. 
  • The interaction among sex, hemoglobin and outcomes in a specialty heart failure clinic. 
  • The molecular regulation of iron metabolism. 
  • Treatment of iron deficiency anemia: are monomeric iron compounds suitable for parenteral administration?